Drug Profile
Research programme: anticancer monoclonal antibodies - AstraZeneca
Alternative Names: Anti-B7-H1 monoclonal antibodies - AstraZenecaLatest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Monoclonal antibodies
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 11 Apr 2012 Preclinical development is ongoing in United Kingdom